AMNOG verändert die Verschreibungspraxis [PDF]
openaire +2 more sources
I tetti sulla spesa per i farmaci nel quadro delle azioni di governo dell’assistenza farmaceutica: criticità e opzioni per una riforma. [PDF]
Jommi C.
europepmc +1 more source
Availability of New Medicines in the US and Germany From 2004 to 2018.
Blankart K, Naci H, Chandra A.
europepmc +1 more source
[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps]. [PDF]
Klimek L +6 more
europepmc +1 more source
Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting. [PDF]
d'Errico M +5 more
europepmc +1 more source
Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose. [PDF]
Schweitzer MK +11 more
europepmc +1 more source
Perspektiven der molekulargenetischen Therapien: Zur Notwendigkeit der Weiterentwicklung des AMNOG Bewertungssystems im Bereich der personalisierten Medizin. [PDF]
Woskowski S, Burgardt C.
europepmc +1 more source
Topics in health economics and social policy : Abstracts of the 7th DIBOGS-Workshop, Düsseldorf 2012 [PDF]
Banduhn, Carolin +8 more
core
Indication-wide drug pricing: Insights from the pharma market. [PDF]
Siegmeier F, Büssgen M.
europepmc +1 more source
OrthoRefine: automated enhancement of prior ortholog identification via synteny. [PDF]
Ludwig J, Mrázek J.
europepmc +1 more source

